KLK3 and prostate cancer: Men harboring pathogenic BRCA2 variants are now advised to initiate prostate cancer screening, prostate-specific antigen (PSA) and digital rectal examination, at younger ages, given elevated risk and the propensity for aggressive tumors [15,16].